
Johnson & Johnson
JNJHealthcare|Drug Manufacturers - General|US
$276.22
+3.90 (+1.43%)
DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04
About
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Stock Price
+47.7%(1Y)
1M
+7.7%
3M
+6.5%
6M
+24.8%
YTD
+33.5%
1Y
+46.6%
3Y
+83.7%
5Y
+69.6%
Pipeline Summary
500 total trials68
Phase 1
49
Phase 2
84
Phase 3
30
Phase 4
Completed: 408Unknown: 17Recruiting: 16Approved: 1Terminated: 27Withdrawn: 14Not Yet Recruiting: 9Active: 8
Active Trials (24)
Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock
NCT06697093Cardiogenic Shock
Recruiting
Enrollment: 500 participants
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
NCT07511166Atrial Fibrillation
Recruiting
Enrollment: 300 participants
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
NCT06993675Multiple Myeloma
Phase 2Recruiting
Enrollment: 50 participants
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504Heart Failure
N/ARecruiting
Enrollment: 250 participants
Positive Fit to Colonoscopy: Closing the Gap
NCT06763432Colorectal Cancer Screening
Recruiting
Enrollment: 45 participants
BioScore
6.2/10
Watchlist
Key Facts
Market Cap$664.95B
Employees138,200 (+0% YoY)
CEOJoaquin Duato
IPO DateJan 2, 1962
Beta0.23
52-Week Range$185.12 – $282.02
Avg Volume7,267,558
ExchangeNYSE
Websitejnj.com
Ownership
Float99.9%
Shares Outstanding2407.3M
Recent Insider Trades
Pinto Daniel EAWARD
Sep 8, 2026113.098 shares
Woods Eugene A.AWARD
Sep 8, 2026135.717 shares
HEWSON MARILLYN AAWARD
Sep 8, 2026180.956 shares
Schmid TimothyOPTION EX.
Sep 2, 202622,527 shares @ $151.41
Schmid TimothyOPTION EX.
Sep 2, 202611,070 shares @ $131.94
Peers
Recent News
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Nov 8, 2026 · gurufocus.com
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Nov 8, 2026 · prnewswire.com
3 Dividend Stocks Worth Researching This Weekend
Nov 8, 2026 · 247wallst.com
Data last updated: Nov 9, 2026, 04:17 AM